[Thesis Title Goes Here]

Total Page:16

File Type:pdf, Size:1020Kb

[Thesis Title Goes Here] THE USE OF A TISSUE ENGINEERED MEDIA EQUIVALENT IN THE STUDY OF A NOVEL SMOOTH MUSCLE CELL PHENOTYPE A Dissertation Presented to The Academic Faculty by JoSette Leigh Briggs Broiles In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in Bioengineering Georgia Institute of Technology April 2008 COPYRIGHT 2008 BY JOSETTE LEIGH BRIGGS BROILES THE USE OF A TISSUE ENGINEERED MEDIA EQUIVALENT IN THE STUDY OF A NOVEL SMOOTH MUSCLE CELL PHENOTYPE Approved by: Dr. Robert M. Nerem, Advisor Dr. Thomas N. Wight School of Mechanical Engineering Hope Heart Program Georgia Institute of Technology Benaroya Research Institute at Virginia Mason Department of Pathology University of Washington Dr. Raymond P. Vito Dr. Elliot Chaikof School of Mechanical Engineering Department of Biomedical Engineering Georgia Institute of Technology Georgia Institute of Technology and Emory University Dr. W. Robert Taylor Department of Biomedical Engineering Georgia Institute of Technology and Emory University Date Approved: December 18, 2007 to Yvette Louise Briggs, the perfect example of a wife-mother-student ACKNOWLEDGEMENTS Before I proceed with my long list of thank-you’s, I must praise God for blessing me with the opportunity to pursue a Ph.D. and surrounding me with wonderful people that have encouraged me throughout this process. My tenure at Georgia Tech has been quite a challenging voyage. This was the first time I experienced repeated failures, was not at the top of the class, and not in complete control of my fortune. I’ve often said that in high school I learned how to navigate social pressures and in undergrad I discovered the meaning of true friendship. But, it has been my graduate school experience that has taught me the most about myself. In the last 6.5 years, I’ve married my best friend and confidante, given birth to two beautiful boys, mourned the loss of nine loved ones, learned how to fail without being a failure, and became inspired to reach and teach others. These moments of joy and tests of faith have humbled me beyond explanation, mellowed my Type A personality, and put my life in proper perspective. OK. Now that I’ve finished my testimony, I will begin my expressions of gratitude. I would like to thank Dr. Robert Nerem for welcoming me into his research lab and to his bottomless well of wisdom, advice, and optimism. I would also like to thank Dr. Thomas Wight for readily providing his expertise and encouragement. Thank you to the members of my committee, Drs. Elliot Chaikof, W. Robert Taylor, and Raymond Vito, for your research direction. I would also like to acknowledge my sources of funding: the National Science Foundation, The National Consortium for Graduate Degrees for Minorities in Engineering and Science, Inc. (GEM), Facilitating Academic - iv - - iv - Careers in Engineering and Science (FACES) Fellowship, George Family Foundation, and the Georgia Tech/Emory Center for the Engineering of Living Tissues. To the Nerem lab members, past and present, thank you for the hundreds of hours of stimulating as well as mindless conversation. Special thanks to Steve Woodard, Dr. Tabassum Ahsan, and Stacey Schutte for the brainstorming sessions and discussions about life philosophies. I would be remiss if I did not acknowledge the hardworking IBB/GTEC staff. I must thank Tracey Couse, Aqua Asberry, Jonafel Crowe, Lisa Cox, Kathy Huggins, Chris Ruffin, and Gloria at the Petit Café’ for your assistance with histology, training on core equipment, the last minute acquisition of signatures, student advisement, administrative assistance, and the hot cups of chicken noodle soup! If it weren’t for my network of Georgia Tech friends, I probably would have made good on one of my many threats to quit school. To Dr. Lori Lowder, Dr. Onyi Irrechukwu, Ima Ebong, Dr. Manu Platt, Drs. Brian and Annica Wayman, and Lola Brown, I say a resounding THANK YOU for your friendship and patient ears. Thanks for providing motivation when I felt incompetent after a botched experiment. Thanks for the distractions when I really should have been working. HA! I’d also like to thank Dr. Gilda Barabino, Dr. Andrew Williams, and Dr. Felicia Benton-Johnson for your mentorship. Your visibility as African American PhDs has inspired me and many others. To my church family and Delta sorors, thanks for providing a balance in my life. Special thanks go to Cindy (Snow) Walker, childcare extraordinaire. You are truly gifted when it comes to working with children. I want to thank your for giving me the peace of mind knowing that Winston was in capable, loving hands while I kept long hours at school. I must thank my sisters Michelle Omari, Crystal Johnson, and v Brandy Nolan. Even though I don’t keep in touch like I should, I know that you “have my back” and will be available whenever I need you. Thanks for being such great and understanding friends. To my extended family, thank you for your prayers and phone calls. Thank you for the road trips to Atlanta and hot plates of mashed potatoes and macaroni-and-cheese awaiting my return home. Thanks for bragging on me even if you don’t know what I do exactly. Finally, I conclude by thanking the most important people in my life. To my dad and brother, Joseph and Jarret Briggs, thanks for your prayers, support and the semiannual marathon phone calls to convince me that all of this is worth it. To my sons, Winston and Solomon, you bring me immense joy and you are my motivation to do better and be better. Damon, you have always been my biggest cheerleader. From the day I received my acceptance letter to those long days and nights I slaved at my laptop writing this dissertation, you have been my rock! I love you more than words could convey. To my mother, Yvette Louise Briggs, even though you are absent in body, I continue to carry your spirit with me. Everyday I strive to emulate you by excelling in my roles as a Christian wife, mother, and servant. vi TABLE OF CONTENTS Page ACKNOWLEDGEMENTS iv LIST OF FIGURES ix LIST OF ABBREVIATIONS xii SUMMARY xv CHAPTER 1 INTRODUCTION 1 Motivation 1 Hypothesis and Specific Aims 3 Significance 4 2 BACKGROUND 5 Arterial Physiology 5 Smooth Muscle Cells 8 Medial Extracellular Matrix 9 Tissue Engineered Blood Vessels 19 3 EXTRACELLULAR MATRIX ARCHITECTURE AND COMPOSITION INFLUENCE TROPOELASTIN EXPRESSION IN SMOOTH MUSCLE CELLS THAT OVEREXPRESS VERSICAN V3 26 Introduction 26 Materials and Methods 28 Results 39 Discussion 64 vii 4 TROPOELASTIN SYNTHESIS BY SMOOTH MUSCLE CELLS THAT OVEREXPRESS V3 VERSICAN IS SENSITIVE TO STIMULATION BY MEDIUM ADDITIVES 68 Introduction 68 Materials and Methods 69 Results 76 Discussion 100 5 MECHANICAL STIMULATION INCREASES TROPOELASTIN SYNTHESIS BY VERSICAN V3 OVEREXPRESSING SMOOTH MUSCLE CELLS IN TISSUE ENGINEERED MEDIA EQUIVALENTS 104 Introduction 104 Materials and Methods 105 Results 115 Discussion 127 6 CONCLUSION AND RECOMMENDATIONS 132 APPENDIX A: SELECTED PROTOCOLS 139 Preparation of Type I Collagen Media Equivalents 140 Preparation of Fibrin Media Equivalents 141 Mechanical Stimulation of Tissue Engineered Media Equivalents 142 Intracellular Staining for Flow Cytometry 144 RNA Isolation from Media Equivalents 146 cDNA Synthesis for Quantitative RT-PCR 148 REFERENCES 150 VITA viii LIST OF FIGURES Page Figure 2.1: Anatomy of the artery 6 Figure 2.2: Forces exerted within the blood vessel 7 Figure 2.3: Elastic fiber conformation 11 Figure 2.4: Elastin binding protein chaperones tropoelastin to the extracellular space 13 Figure 2.5: Tropoelastin incorporation into elastic fibers 14 Figure 2.6: Structure of versican isoforms 17 Figure 3.1: Schematic of TEME fabrication 31 Figure 3.2: Light microscopy images of LXSN and LV3SN cells 40 Figure 3.3: Confocal imaging of intracellular tropoelastin. 41 Figure 3.4: Disk shaped collagen and fibrin TEMEs have distinct appearances 43 Figure 3.5: Compaction of collagen TEMEs 44 Figure 3.6: Compaction of fibrin TEMEs 44 Figure 3.7: Modified Movat’s Pentachrome staining of collagen TEMEs 45 Figure 3.8: Orcein staining of collagen TEMEs 46 Figure 3.9: Immunohistochemical staining for tropoelastin in collagen TEMEs 47 Figure 3.10: Versican and tropoelastin gene expression varies with matrix structure and composition after one day in culture 50 Figure 3.11: Versican and tropoelastin gene expression varies with matrix structure and composition after seven days in culture 51 Figure 3.12: LXSN and LV3SN cells contain equal amounts of DNA per cell 52 Figure 3.13: DNA content in collagen TEMEs 54 Figure 3.14: DNA content in fibrin TEMEs 54 Figure 3.15: Changes in LXSN DNA content relative to matrix type 55 ix Figure 3.16: Changes in LV3SN DNA content relative to matrix type. 55 Figure 3.17: Western analysis of tropoelastin protein expression in whole lysates of cell monolayers, collagen TEMEs and fibrin TEMEs 58 Figure 3.18: Western analysis of tropoelastin secreted into the spent media of monolayer, collagen TEMEs, and fibrin TEMEs cultures 58 Figure 3.19: Flow cytometry assessment of versican and tropoelastin in monolayers 60 Figure 3.20: Flow cytometry assessment of versican and tropoelastin in collagen TEMEs 61 Figure 3.21: Flow cytometry assessment of versican and tropoelastin in fibrin TEMEs 62 Figure 4.1: Experimental timeline for stimulation with medium additives 71 Figure 4.2: Light microscopy of monolayers after one day of chondroitin sulfate and chondroitinase stimulation 77 Figure 4.3: Light microscopy of monolayers after one day of TGF-β1 stimulation. 78 Figure 4.4: DNA content in TEMEs after one day of exposure to medium additives 80 Figure 4.5: DNA content in TEMEs after seven days of exposure to medium additives 80 Figure 4.6: Versican gene expression in monolayers after one day of exposure to medium additives 82 Figure 4.7: Tropoelastin gene expression in monolayers after one day of exposure to medium additives 83 Figure 4.8: Confocal microscopy of intracellular tropoelastin in LV3SN monolayers treated with medium additives.
Recommended publications
  • Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke
    International Journal of Molecular Sciences Review Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke Yun Hwa Choi 1, Collin Laaker 2, Martin Hsu 2, Peter Cismaru 3, Matyas Sandor 4 and Zsuzsanna Fabry 2,4,* 1 School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA; ychoi253@wisc.edu 2 Neuroscience Training Program, University of Wisconsin-Madison, Madison, WI 53705, USA; claaker@wisc.edu (C.L.); mhsu24@wisc.edu (M.H.) 3 Chemistry, University of Wisconsin-Madison, Madison, WI 53705, USA; pcismaru@wisc.edu 4 Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA; msandor@wisc.edu * Correspondence: zfabry@wisc.edu Abstract: Stroke disrupts the homeostatic balance within the brain and is associated with a significant accumulation of necrotic cellular debris, fluid, and peripheral immune cells in the central nervous system (CNS). Additionally, cells, antigens, and other factors exit the brain into the periphery via damaged blood–brain barrier cells, glymphatic transport mechanisms, and lymphatic vessels, which dramatically influence the systemic immune response and lead to complex neuroimmune communi- cation. As a result, the immunological response after stroke is a highly dynamic event that involves communication between multiple organ systems and cell types, with significant consequences on not only the initial stroke tissue injury but long-term recovery in the CNS. In this review, we discuss the complex immunological and physiological interactions that occur after stroke with a focus on how the peripheral immune system and CNS communicate to regulate post-stroke brain homeostasis. First, Citation: Choi, Y.H.; Laaker, C.; Hsu, we discuss the post-stroke immune cascade across different contexts as well as homeostatic regulation M.; Cismaru, P.; Sandor, M.; Fabry, Z.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0026032 A1 ZUBERY Et Al
    US 2008.0026.032A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0026032 A1 ZUBERY et al. (43) Pub. Date: Jan. 31, 2008 (54) COMPOSITE IMPLANTS FOR PROMOTING Publication Classification BONE REGENERATION AND (51) Int. Cl. AUGMENTATION AND METHODS FOR A6F 2/00 (2006.01) THER PREPARATION AND USE A638/00 (2006.01) A6IP 9/00 (2006.01) (76) Inventors: Yuval ZUBERY, Cochav Yair (52) U.S. Cl. ............................................ 424/423: 514/2 (IL); Arie Goldlust, Ness Ziona (57) ABSTRACT (IL); Thomas Bayer, Tel-Aviv (IL); Eran Nir, Rehovot (IL) Collagen based matrices cross-linked by a reducing Sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two Correspondence Address: layers including reducing Sugar cross-linked collagen matri DANEL, SWIRSKY ces of different densities. The composite matrices may be 55 REUVEN ST. used in bone regeneration and/or augmentation applications. BET SHEMESH 99.544 Scaffolds including glycated and/or reducing Sugar cross linked collagen exhibit improved support for cell prolifera (21) Appl. No.: 11/829,111 tion and/or growth and/or differentiation. The denser col lagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later func (22) Filed: Jul. 27, 2007 tioning as an ossification Supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross Related U.S. Application Data linking the collagen(s) using a reducing Sugar or a mixture (60) Provisional application No. 60/833,476, filed on Jul.
    [Show full text]
  • Basic Structure of the Villous Trees
    6 Basic Structure of the Villous Trees M. Castellucci and P. Kaufmann Nearly the entire maternofetal and fetomaternal exchange Syncytiotrophoblast takes place in the placental villi. There is only a limited contribution to this exchange by the extraplacental mem- Syncytium or Multinucleated Giant Cells? branes. In addition, most metabolic and endocrine activi- The syncytiotrophoblast is a continuous, normally unin- ties of the placenta have been localized in the villi (for terrupted layer that extends over the surfaces of all villous review, see Gröschel-Stewart, 1981; Miller & Thiede, 1984; trees as well as over parts of the inner surfaces of chori- Knobil & Neill, 1993; Polin et al., 2004). onic and basal plates. It thus lines the intervillous Throughout placental development, different types of space. Systematic electron microscopic studies of the syn- villi emerge that have differing structural and functional cytial layer (e.g., Bargmann & Knoop, 1959; Schiebler & specializations. Despite this diversification, all villi exhibit Kaufmann, 1969; Boyd & Hamilton, 1970; Kaufmann the same basic structure (Fig. 6.1): & Stegner, 1972; Schweikhart & Kaufmann, 1977; Wang • They are covered by syncytiotrophoblast, an epithelial & Schneider, 1987) have revealed no evidence that the surface layer that separates the villous interior from syncytiotrophoblast is composed of separate units. Rather, the maternal blood, which flows around the villi. Unlike it is a single continuous structure for every placenta. Only other epithelia, the syncytiotrophoblast is not com- in later stages of pregnancy, as a consequence of focal posed of individual cells but represents a continuous, degeneration of syncytiotrophoblast, fibrinoid plaques uninterrupted, multinucleated surface layer without may isolate small islands of syncytiotrophoblast from the separating cell borders (Fig.
    [Show full text]
  • Tamm-Horsfall Glycoprotein Enhances PMN Phagocytosis by Binding to Cell Surface-Expressed Lactoferrin and Cathepsin G That Activates MAP Kinase Pathway
    Molecules 2011, 16, 2119-2134; doi:10.3390/molecules16032119 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Tamm-Horsfall Glycoprotein Enhances PMN Phagocytosis by Binding to Cell Surface-Expressed Lactoferrin and Cathepsin G That Activates MAP Kinase Pathway Syue-Cian Siao 1, Ko-Jen Li 2, Song-Chou Hsieh 2, Cheng-Han Wu 2, Ming-Chi Lu 3, Chang-Youh Tsai 4 and Chia-Li Yu 1,2,* 1 Institute of Molecular Medicine, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei 100, Taiwan 2 Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei 100, Taiwan 3 Division of Allergy, Immunology and Rheumatology, Buddhist Dalin Tzu-Chi General Hospital, No. 2 Ming-Shen Road, Dalin, Chia-Yi, Taiwan 4 Section of Allergy, Immunology and Rheumatology, Taipei-Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 11217, Taiwan * Author to whom correspondence should be addressed; E-Mail: chialiyu@ntu.edu.tw; Tel.: +886-2-23123456 Ext.65011; Fax: +886-2-23957801. Received: 7 December 2010; in revised form: 15 February 2011 / Accepted: 28 February 2011 / Published: 3 March 2011 Abstract: The molecular basis of polymorphonuclear neutrophil (PMN) phagocytosis-enhancing activity (PEA) by human purified urinary Tamm-Horsfall glyco- protein (THP) has not been elucidated. In this study, we found human THP bound to lactoferrin (LF) and cathepsin G (CG) expressed on the surface of PMN, identified by a proteomic study with MALDI-TOF- LC/LC/mass spectrometric analysis.
    [Show full text]
  • Immunohistochemistry Reference Guide, Vol
    Immunohistochemistry reference guide, vol. 10 New Products CD71 (MRQ-48) Androgen Receptor (SP107) . 13 CD23 (MRQ-57) . 46 Arginase-1 (SP156) . 15 CD23 (SP23) . 46 BCL2 (SP66) . 18 CD33 (PWS44) . 50 BCL6 (SP155) . 19 CD38 (SP149) . 53 BOB.1 (SP92) . 22 CD43 (SP55) . 54 C3d (polyclonal) . 23 CD56 (MRQ-42) . 59 C4d (SP91) . 24 CD71 (MRQ-48) . 64 Calcitonin (SP17) . 27 CD79a (SP18) . 66 Calretinin (SP13) . 30 CD99 (SP119) . 67 Carbonic Anhydrase IX (CA IX) CD138 (SP152) . 69 (MRQ-54 (also known as M75)) . 31 CMV (8B1 .2, 1G5 .2 & 2D4 .2) . 75 CD1a (EP3622‡) . 32 Cytokeratin 14 (SP53) . 86 CD3 (MRQ-39) . 34 Diamond TBS Antibody Diluent . 231 CD7 (MRQ-56) . 37 Epstein-Barr Virus (MRQ-47) . 99 CD8 (SP16) . 38 FoxP1 (SP133) . .105 CD11c (5D11) . 40 Hemoglobin A (EPR3608‡) . 119 CD20 (SP32) . 44 Her2/Neu (SP3) . 123 S100P (16/f5) Herpes Simplex Virus I (10A3) . 124 Progesterone Receptor (SP42) . 192 HGAL (MRQ-49) . 126 S100P (16/f5) . 199 IgG4 (MRQ-44) . 134 Smoothelin (R4A) . .200 KBA.62 . 140 SOX-2 (SP76) . 202 LMO2 (SP51) . 145 SOX-11 (MRQ-58) . 203 MSH6 (SP93) . 155 Synaptophysin (MRQ-40) . .206 MUM1 (MRQ-43) . 160 T-bet (MRQ-46) . 207 Myeloperoxidase (SP72) . .162 TBS IHC Wash Buffer + Tween® 20 . 231 Napsin A (MRQ-60) . 166 TdT (SP150) . 210 NSE (MRQ-55) . 169 TFE3 (MRQ-37) . 211 p53 (SP5) . .174 Thyroglobulin (MRQ-41) . .213 PAX-8 (MRQ-50) . .182 TIA-1 (EP243‡) . .214 PAX-8 (polyclonal) . .182 Uroplakin III (SP73) . 221 PBS IHC Wash Buffer + Tween® 20 . 231 Varicella Zoster Virus (multiple clones) .
    [Show full text]
  • 2021 Clinical Diagnostic Laboratory Fee Schedule CPT Codes, Descriptions and Other Data Only Are Copyright 2021 American Medical Association
    2021 Clinical Diagnostic Laboratory Fee Schedule CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association (AMA). YEAR HCPCS MOD EFF_DATE INDICATOR RATE2021 SHORTDESC LONGDESC 2021 0001U 20210101 N 00720.00 Rbc dna hea 35 ag 11 bld grp Red blood cell typing 2021 0002M 20210101 N 00503.40 Liver dis 10 assays w/ash Liver disease, ten biochemical assays (alt, a2-macroglobulin, apolipoprotein 2021 0002U 20210101 N 00025.00 Onc clrct 3 ur metab alg plp Measurement of substances in urine to predict likelihood of polyps in large 2021 0003M 20210101 N 00503.40 Liver dis 10 assays w/nash Liver disease, ten biochemical assays (alt, a2-macroglobulin, apolipoprotein 2021 0003U 20210101 N 00950.00 Onc ovar 5 prtn ser alg scor Measurement of proteins associated with ovarian cancer in serum 2021 0004M 20210101 N 00079.00 Scoliosis dna alys Scoliosis, dna analysis of 53 single nucleotide polymorphisms (snps), using 2021 0005U 20210101 N 00760.00 Onco prst8 3 gene ur alg Test for detecting genes associated with prostate cancer in urine 2021 0006M 20210101 N 00150.00 Onc hep gene risk classifier Oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh 2021 0007M 20210101 N 00375.00 Onc gastro 51 gene nomogram Oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression 2021 0007U 20210101 N 00114.43 Rx test prsmv ur w/def conf Testing for presence of drug in urine 2021 0008U 20210101 N 00597.91 Hpylori
    [Show full text]
  • 2020 Clinical Diagnostic Laboratory Fee Schedule CPT Codes, Descriptions and Other Data Only Are Copyright 2018 American Medical Association
    2020 Clinical Diagnostic Laboratory Fee Schedule CPT codes, descriptions and other data only are copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association (AMA). Codes in green are enddated. NOTE: Zero pay (0.00) codes will be reimbursed at 65% of billed charges ** The appearance on this schedule of a code and rate is not an indication of coverage , nor a guarantee of payment. HCPCS MODIFIER SHORT DESCRIPTION RATE 2020 End Date 0001U Rbc dna hea 35 ag 11 bld grp $720.00 0002M Liver dis 10 assays w/ash $503.40 0002U Onc clrct 3 ur metab alg plp $25.00 0003M Liver dis 10 assays w/nash $503.40 0003U Onc ovar 5 prtn ser alg scor $950.00 0004M Scoliosis dna alys $79.00 0005U Onco prst8 3 gene ur alg $760.00 0006M Onc hep gene risk classifier $150.00 0006U Detc ia meds 120+ analytes $246.92 0007M Onc gastro 51 gene nomogram $375.00 0007U Rx test prsmv ur w/def conf $114.43 0008U Hpylori detcj abx rstnc dna $597.91 0009U Onc brst ca erbb2 amp/nonamp $107.00 0010U Nfct ds strn typ whl gen seq $427.26 0011M Onc prst8 ca mrna 12 gen alg $760.00 0011U Rx mntr lc-ms/ms oral fluid $114.43 0012M Onc mrna 5 gen rsk urthl ca $760.00 0012U Germln do gene reargmt detcj $2,515.60 0013M Onc mrna 5 gen recr urthl ca $760.00 0013U Onc sld org neo gene reargmt $2,515.60 0014U Hem hmtlmf neo gene reargmt $2,515.60 0016U Onc hmtlmf neo rna bcr/abl1 $163.96 0017U Onc hmtlmf neo jak2 mut dna $91.66 0018U Onc thyr 10 microrna seq alg $3,002.09 0019U Onc rna tiss predict alg $3,675.00 0021U
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,652,507 B2 Kizer Et Al
    US008652507 B2 (12) United States Patent (10) Patent No.: US 8,652,507 B2 Kizer et al. (45) Date of Patent: *Feb. 18, 2014 (54) JUVENILE CARTILAGE COMPOSITION (56) References Cited (75) Inventors: Neil Kizer, Crestwood, MO (US); U.S. PATENT DOCUMENTS Robert Spiro, Half Moon Bay, CA (US); 1,347,622 A 7/1920 Deininger Jian Yao, Austin, TX (US); Cheryl 2,533,004 A 12/1950 Ferry et al. Renee Blanchard, Warsaw, IN (US) 2,621,145 A 12/1952 Sano 3,400,199 A 9, 1968 Balassa 3,474,146 A 10, 1969 Baker et al. (73) Assignee: Zimmer, Inc., Warsaw, IN (US) 3,476,855 A 11/1969 Balassa 3,478,146 A 11/1969 Balassa (*) Notice: Subject to any disclaimer, the term of this 3,772,432 A 11/1973 Balassal patent is extended or adjusted under 35 RE28,093 E 7, 1974 Balassa 3,966,908 A 6, 1976 Balassa U.S.C. 154(b) by 43 days. 4,440,680 A 4, 1984 Cioca This patent is Subject to a terminal dis 4,453,939 A 6, 1984 Zimmerman et al. claimer. 4,479,271 A 10/1984 Bolesky et al. 4,522,096 A 6/1985 Niven, Jr. 4,566,138 A 1/1986 Lewis et al. (21) Appl. No.: 12/976,711 4,587,766 A 5/1986 Miyatake et al. (22) Filed: Dec. 22, 2010 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2012/OOO9224A1 Jan. 12, 2012 AU 1998.71003 B2 10, 1998 AU 2006282754 A2 3, 2007 (Continued) Related U.S.
    [Show full text]
  • Expanding the Chondroitin Sulfate Glycoproteome — but How Far?
    fcell-09-695970 August 9, 2021 Time: 12:32 # 1 MINI REVIEW published: 13 August 2021 doi: 10.3389/fcell.2021.695970 Expanding the Chondroitin Sulfate Glycoproteome — But How Far? Fredrik Noborn1*, Mahnaz Nikpour1, Andrea Persson1, Jonas Nilsson1,2 and Göran Larson1 1 Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, 2 Proteomics Core Facility, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden Chondroitin sulfate proteoglycans (CSPGs) are found at cell surfaces and in connective tissues, where they interact with a multitude of proteins involved in various pathophysiological processes. From a methodological perspective, the identification of CSPGs is challenging, as the identification requires the combined sequencing of specific core proteins, together with the characterization of the CS polysaccharide modification(s). According to the current notion of CSPGs, they are often considered in relation to a functional role in which a given proteoglycan regulates a specific function in cellular physiology. Recent advances in glycoproteomic methods have, however, enabled the identification of numerous novel chondroitin sulfate core proteins, and their glycosaminoglycan attachment sites, in humans and in various animal models. Edited by: John Whitelock, In addition, these methods have revealed unexpected structural complexity even in University of New South Wales, the linkage regions. These findings indicate that the number and structural complexity Australia of CSPGs are much greater than previously perceived. In light of these findings, the Reviewed by: prospect of finding additional CSPGs, using improved methods for structural and Jasmeen S. Merzaban, King Abdullah University of Science functional characterizations, and studying novel sample matrices in humans and in and Technology, Saudi Arabia animal models is discussed.
    [Show full text]
  • 20.310J Molecular, Cellular, and Tissue Biomechanics
    Cardiovascular Tissues Musculoskeletal Tissues Courtesy of Ernst B. Hunziker. Used with permission. © source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. 1 Musculoskeletal Tissues Tension Compression & Shear © ADAM, Inc. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. 2 Tendon Pro-collagen molecule _ © Taylor & Francis Group. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. Source: Kastelic, J., A. Galeski, et al. "The Multicomposite Structure of Tendon." Connective Tissue Research 6, no. 1 (1978): 11-23. E~1 GPa Force - extension Fit by WLC model Courtesy of Elsevier, Inc., http://www.sciencedirect.com. Used with permission. Source: Gutsmann, Thomas. "Force Spectroscopy of Collagen Fibers to Investigate their Mechanical Properties and Structural Organization." Biophysical Journal 86, no. 5 (2004): 3186-93. Stress vs strain curve of a rat tail tendon: (A-B) Toe - heel region, (Sun+, J Biomechanics, 2004) (C) linear region, (D) plateau, Courtesy of Elsevier, Inc., http://www.sciencedirect.com. Used with permission. (E) rupture of the tendon. Source: Sun, Yu-Long, et al. "Stretching Type II Collagen with Optical Tweezers." Journal of Biomechanics 37, no. 11 (2004): 1665-9. (Gutsmann+, Biophys J, 2004) 3 Cell ~ 60μm long Intracellular Fibricarrier Protruding Fibripositor © source unknown. All rights reserved. This content is excluded from our Creative Courtesy of Karl E. Kadler. Used with permission.
    [Show full text]
  • Structure and Biology of the Intervertebral Disk in Health and Disease
    Structure and Biology of the Intervertebral Disk in Health and Disease Wilson C.W. Chan, PhDa, Kit Ling Sze, PhDa, Dino Samartzis, DScb, Victor Y.L. Leung, PhDc, Danny Chan, PhDa,* KEYWORDS Intervertebral disk Degeneration Extracellular matrix Development Biology Low back pain is a leading debilitating condition sixth and seventh decade of life.24,25 However, that affects every population worldwide,1 and the development or, rather, severity of IVD degen- can lead to diminished physical function, loss of eration is not linearly based on age; degenerative wages, decreased quality of life, and psycholog- changes can be noted in young children and not ical distress.1–4 In fact, chronic low back pain yet be manifested in other adults.19,24 Overall, the may also lead to brain tissue destruction.5–8 As true prevalence of IVD degeneration in populations a consequence, low back pain is one of the most has yet to be determined, due to improper surveil- common conditions for which to seek medical lance methods (ie, patient-based versus consultation and one of those preeminent for anal- population-based), sampling issues, heterogeneity gesic use in the United States.3,4 Furthermore, the in the operational definition and imaging modalities management of patients with low back pain can be in assessing the phenotype of disk changes, and an a challenge, often requiring a multidisciplinary incomplete understanding of the risk-factor profile approach to treatment (see the article by Karppi- and its interaction effects that may affect degener- nen and colleagues elsewhere in this issue).9–13 ative changes and their manifestation in different Although low back pain is a multifactorial condi- age, gender, and ethnic groups.14,15,26 Along these tion (eg, biopsychological, muscular, socioeco- lines, the incidence rates of annular tears, disk nomic), intervertebral disk (IVD) degeneration has bulging, and endplate defects/abnormalities are been indicated to be a strong etiologic factor also not conclusive, and vary between studies.
    [Show full text]
  • Part 2. Proteins
    Proteins Part 2. Proteins White & White — Proteins, Peptides & Amino Acids SourceBook 5 Proteins 4-IBBL Acid Glycoprotein VI, α1- PeproTech 310-11 Human recombinant, expressed in E. coli Synonyms: Orosomucoid MW 19.5k >98% (SDS-PAGE) & HPLC; <0.1 ng endotoxin per Fluka 50646 Human plasma MW 45k ≥98% (GE); 60% mg (1EU/mg); lyophilized | Member of the emerging family of protein; 6% water | Arnaud, P et al, Meth Enzymol, 163: 418, ligands with structural homology to tumor necrosis factor; 185 AA; 1988; Eap, CB & Baumann, P, Electrophoresis, 9: 650, 1988 ED50 < 10ng/mL; SA determined by the dose-dependent stimulation of IL-8 production by human PBMC Acid Glycoprotein, α1- α 6CKINE Synonyms: Orosomucoid; Seromucoid, 1- Synonyms: Exodus II; SLC; T-Cell Activation Gene IV Fluka 50647 Bovine serum ≥99% (gel electrophoresis); ≤5% Biodesign A52013M E. coli Purified | Species specificity: water; ~70% protein mouse Biodesign A50106H Human Purified Biodesign A52035H E. coli Purified Fitzgerald 30-AA01 Human plasma High purity | Chemicon GF086 Human ≥95% Orosomucoid ICN 153905 Human plasma MW 44.1k Lyophilized, salt Biogenesis 4396-0150 Human r-DNA Lyophilized free, >99% BioSource International PHC1474 Human recombinant ICN 191348 Human plasma MW 44.1k Lyophilized, salt PeproTech 300-35 Human recombinant, expressed in E. coli free, >99% (SDS-PAGE) | Negative for HBs Ag & HIV antibodies; MW 12.2k >98% (SDS-PAGE) & HPLC; <0.1 ng endotoxin per Schmid, K etal, Biochemistry, 12:2711, 1973 mg (1EU/mg); lyophilized | In the CC chemokine family; similar to Scipac P153-0 Orosomucoid, from serum/plasma >99%; Exodus-1 (aka MIP-3α & LARC); inhibits hemopoiesis & stimulating lyophilized | Acute phase serum protein chemotaxis; 111 AA; SA determined by its ability to chemoattract total lymphocyte population Scipac P153-1 Orosomucoid, from serum/plasma >96%; lyophilized | Acute phase serum protein Sigma C 0720 Human recombinant, expressed in E.
    [Show full text]